Skip to content

The efficacy of hachimijiogan for Alzheimers disease

A multicenter, placebo-controlled, randomized trial to evaluate the efficacy and safety of hachimijiogan in patients with mild Alzheimer's disease

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041260016
Enrollment
200
Registered
2026-04-28
Start date
2026-04-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild Alzheimers disease Hachimijiogan, mild Alzheimers disease

Interventions

Subjects will be randomized based on age, sex,and will be administered either hachimijiogan Extract Granules (7.5g, 3 times a day before meals (or after meals)) or a placebo for 6 months.

Sponsors

Kainuma Mosaburo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 60 to under 85 years old 2) Patients with Alzheimers dementia (those who meet the diagnostic criteria for Alzheimers dementia according to DSM-5) 3) Those with a baseline MMSE score of 15 to 26 4) Those with a baseline ABC dementia scale score of 86 to 100 or CDR 1.0 5) Patients who have been using donepezil, galantamine, or rivastigmine at a fixed dose for the past three months. 6) Patients who have signed an informed consent form for participation in the study, who can be contacted frequently by the patient, and who have a trustworthy study partner (parents, siblings, children/grandchildren, relatives living in the same household, or persons considered to be equivalent to such close relatives) who can respond at designated times.

Exclusion criteria

Exclusion criteria: 1) Receiving non-pharmacological therapy for the treatment of AD 2) Taking Kampo Medicine 3)Regularly consume health functional foods that may influence the study three or more times per week and cannot discontinue them within three weeks prior to the study start date 4)Prior experience of anti-amyloid beta antibody drug therapy 5) Taking Memantine 6) Kidney disfunction (eGFR100mg/dl 8)Change of drug dosage or type that could affect the progression cognitive function during the three months 9) Complication with gastric ulcer, bronchial asthma, or epilepsy. 10) Judged by doctors not to be suited for study, such as having serious complications

Design outcomes

Primary

MeasureTime frame
ADAS-Jcog

Secondary

MeasureTime frame
Disability assessment of Dementia Grip strength Advanced Glycation End Products

Contacts

Public ContactMosaburo Kainuma

Universtiy of Toyama

kainuma@med.u-toyama.ac.jp+81-76-434-7393

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026